Treatment status of non-small cell lung cancer with METexon14 skipping mutation
10.3760/cma.j.cn371439-20220930-00007
- VernacularTitle:MET14外显子跳跃突变非小细胞肺癌的治疗现状
- Author:
Jingxian ZHANG
1
;
Jianfei SU
;
Xueqin WEI
;
Dan YI
;
Xiaojiang LI
Author Information
1. 天津中医药大学第一附属医院肿瘤科 国家中医针灸临床医学研究中心，天津 300380
- Keywords:
Carcinoma, non-small-cell lung;
MET exon14 skipping mutation;
Molecular targeted therapy
- From:
Journal of International Oncology
2023;50(1):37-41
- CountryChina
- Language:Chinese
-
Abstract:
MET exon14 (METex14) skipping mutation is an independent driver gene in non-small cell lung cancer (NSCLC) . About 3%-4% of NSCLC patients carry METex14 skipping mutation. These patients have poor prognoses and poor responses to traditional chemotherapy and immunotherapy. Highly selective MET inhibitors such as capmatinib, tepotinib, savolitinib have shown good efficacy and safety data in clinical trials, which bring new treatment options for patients with METex14 skipping mutations.
